Compare Novo Nordisk A/S (NVO) vs Tidewater Inc (TDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Tidewater Inc — how do they compare? Novo Nordisk A/S trades at $45.04 (market cap $198.57B), while Tidewater Inc trades at $92.78 (market cap $4.63B). The key difference: Novo Nordisk A/S is far larger — about 42.9× Tidewater Inc's market cap, and Novo Nordisk A/S pays a 4.03% dividend while Tidewater Inc pays none. Which is the better fit depends on your goals.
| NVO | TDW | |
|---|---|---|
Market Cap | $198.57B | $4.63B |
Sector | Health | Utilities |
52-Week High | $63.98 | $100.61 |
52-Week Low | $35.29 | $47.29 |
Enterprise Value | $213.37B | $4.67B |
Dividend Yield | 4.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Tidewater (TDW) trades at $92.00, down 2.4% on the day, with a bullish technical signal supported by moving averages and a consensus price target of $105.50. Recent Q2 2026 earnings of $0.43 per share beat expectations, while the company completed the Wilson Sons Ultratug acquisition in August 2026, signaling growth in offshore energy services. Financial health is solid with a net income margin of 18.34% and strong cash flow from operations of $379.11 million in 2025.
The outlook is cautiously optimistic, with upside potential from analyst targets and operational strength, but risks include earnings volatility, as seen in Q1 and Q2 2026 misses, and exposure to energy market fluctuations. Investor sentiment is mixed, with a majority hold rating from analysts, suggesting a balanced view amid acquisition integration and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Tidewater Inc
Tidewater is the leading global provider of offshore support vessels (OSVs) to the energy industry. With the world's largest fleet of platform supply vessels (PSVs) and anchor handling tugs (AHTS), it provides critical logistics and marine support for offshore oil, gas, and renewable energy projects. Following a period of massive strategic consolidation, Tidewater is now focused on maximizing day rates and free cash flow in a supply-constrained market, positioning itself as a primary beneficiary of the multi-year offshore upcycle.
Read more on TDW →
